Anoro Ellipta side effects Anoro Ellipta can cause mild or serious side effects. The following lists contain some of the key side effects that may occur while taking Anoro Ellipta. These lists do not ...

The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive ...

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ...

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...

GlaxoSmithKline and Innovia announced new data at the American Thoracic Society (ATS) 2016 International Conference regarding the safety and efficacy of Anoro Ellipta ...

LONDON — GlaxoSmithKline and Theravance on Monday announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), a once-daily that combines two long-acting bronchodilators in a single ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US ...

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ANORO ELLIPTA contains the active ingredients umeclidinium bromide and ...